Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932501 · ClinicalTrials.gov registry record
Medication-related Osteonecrosis of the Jaw (MRONJ) Registry
A clinical trial of Bisphosphonate-Associated Osteonecrosis of the Jaw and Medication-related Osteonecrosis of the Jaw, sponsored by AO Clinical Investigation and Publishing Documentation.
- Active
- Registry status
- 518
- Enrollment target
- 14
- Study locations
NCT02932501: Active study of Bisphosphonate-Associated Osteonecrosis of the Jaw and Medication-related Osteonecrosis of the Jaw, sponsored by AO Clinical Investigation and Publishing Documentation.
NCT02932501 is a study of Bisphosphonate-Associated Osteonecrosis of the Jaw and Medication-related Osteonecrosis of the Jaw that is active but no longer recruiting, run by AO Clinical Investigation and Publishing Documentation. The registered enrollment target is 518 participants. The trial reports 14 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02932501, a study of Bisphosphonate-Associated Osteonecrosis of the Jaw and Medication-related Osteonecrosis of the Jaw, is active but no longer recruiting, sponsored by AO Clinical Investigation and Publishing Documentation.
- ACTIVE NOT RECRUITING
- Registry status
- 518 participants
- Enrollment target
- 14
- Study locations
Study Summary
Approximately 500 patients will be included in this patient registry. Data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and antiangiogenic drugs , degree and extension of osteonecrosis, osteonecrosis-specific treatment, outcomes and complications within 1 year after treatment.
Conditions Studied
Interventions
- PROCEDURE Surgical treatment
- PROCEDURE Conservative treatment
- PROCEDURE Adjuvant non-surgical treatment
Study Locations (14)
Other
- Helsinki University Hospital - Helsinki
- Charité - Universitätsmedizin Berlin - Berlin
- Universitätskliniken Eppendorf - Hamburg
- Ludwig-Maximilians University Munich, Klinik und Poliklinik für Mund-, Kiefer und Gesichtschirurgie - München
- Eramus MC - Rotterdam
- Hamad Medical Corporation - Doha
- Emergency Clinical County Hospital of Constanta - Constanța
- University Medical Centre Ljubljana - Ljubljana
- Kyungpool National University - Daegu
- 12 de Octubre University Hospital - Madrid
- Universitätsspital Basel - Basel
- Luzerner Kantonsspital - Lucerne
- Universitätsspital Zürich - Zurich
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2024-04 |
What the registry record for NCT02932501 still lists
NCT02932501 is an observational study that tracks outcomes without assigning an intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Bisphosphonate-Associated Osteonecrosis of the Jaw appearing as the primary indexed condition, and to 3 interventions - of which Surgical treatment is the first listed.
NCT02932501 lists 14 locations in 2 states (Other, Kentucky).
Frequently Asked Questions
What is clinical trial NCT02932501 about?
NCT02932501 is a clinical study titled "Medication-related Osteonecrosis of the Jaw (MRONJ) Registry". Approximately 500 patients will be included in this patient registry. Data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and antiangiogenic drugs , degree and extension of osteonecrosis, osteonecrosis-specific treatment, outcomes and comp...
What is the current status of trial NCT02932501?
This trial is currently active not recruiting. The enrollment target is 518 participants. The study started on 2017-08-14. Estimated completion is 2024-04.
What conditions does trial NCT02932501 study?
This clinical trial studies the following conditions: Bisphosphonate-Associated Osteonecrosis of the Jaw, Medication-related Osteonecrosis of the Jaw.
What interventions are being tested in trial NCT02932501?
The interventions under investigation include: Surgical treatment (PROCEDURE), Conservative treatment (PROCEDURE), Adjuvant non-surgical treatment (PROCEDURE).
Who is sponsoring clinical trial NCT02932501?
This trial is sponsored by AO Clinical Investigation and Publishing Documentation, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02932501 being conducted?
This trial has 14 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bisphosphonate-Associated Osteonecrosis of the Jaw
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI